Filspari (sparsentan) — NDA/BLA submission
2026
Renalys, now Chugai, announced positive topline results from its Phase 3 clinical study of Filspari in Japanese patients with IgAN and plans to submit an NDA in Japan in 2026.Source filing
LGND biotech catalysts & pipeline
LIGAND PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
ersodetug — Topline data
H2 2026
The company expects to announce topline results for the fully enrolled open-label study in the second half of 2026.Source filing
Qtorin 3.9% rapamycin anhydrous gel (Qtorin rapamycin) — NDA/BLA submission
H2 2026
Palvella remains on track to submit the remaining modules and complete the NDA submission in the second half of 2026.Source filing
volixibat — Topline data
in Q1 2027
On August 5, 2026, our partner announced enrollment was completed in the VANTAGE Phase 2b study of volixibat in cholestatic pruritus due to primary biliary cholangitis (PBC) with topline results expected in Q1 2027.Source filing
avim therapy — Topline data
Q2 2027
Orchestra BioMed is targeting top line data in the second quarter of 2027.Source filing
lasofoxifene — Topline data
H2 2027
The Company expects to complete enrollment of the Phase 3 ELAINE-3 clinical trial in the fourth quarter of 2026 and to have topline data in the second half of 2027.Source filing
Qtorin 3.9% rapamycin anhydrous gel (Qtorin rapamycin) — Topline data
H2 2027
Topline results from the Phase 2 trial are expected in the second half of 2027.Source filing
Qarziba — Topline data
2028
Results from the BEACON-2 trial are expected in 2028.Source filing